BACKGROUND
Iovance Biotherapeutics aims to improve patient care for people living with cancer. Iovance is investigating T cell-based therapies, known as tumor infiltrating lymphocytes (TIL), which use a patient’s own immune cells to attack cancer.
REQUIREMENTS FULFILLED BY SKYLAND PIMS®
- FDA validatable environment
- End-to-end manufacturing and quality data repository
- Real-time view of batch data from CMOs
- Implement system for internal manufacturing (2022)
- 21 CFR Part 11 compliant
- Low Total Cost of Ownership (TCO)
- Central management of all data
- Easy, intuitive interface
- Streamline tech transfer
- Compatible with current and future automation systems
